Evidence map›Paper›PMID 39188594›Full record

ArticleTechnical innovations & patient support in radiation oncology2024

The value of PROMs for predicting erectile dysfunction in prostate cancer patients with Bayesian network.

Biche Osong, Hajar Hasannejadasl, Henk van der Poel, Ben Vanneste, Joep van Roermund, Katja Aben, Johan Van Soest, Inge Van Oort, Laura Hochstenbach, Esther J Bloemen-van Gurp and 2 more

Abstract read
In one paragraph

Article in Technical innovations & patient support in radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Biche OsongDepartment of Radiation Oncology (MAASTRO), Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands.
Hajar HasannejadaslDepartment of Radiation Oncology (MAASTRO), Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands.
Henk van der PoelDepartment of Urology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Ben VannesteDepartment of Radiation Oncology (MAASTRO), Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands.
Joep van RoermundDepartment of Urology, Maastricht University Medical Center, the Netherlands.
Katja AbenDepartment of Research Development, Netherlands Comprehensive Cancer Organization, Utrecht, the Netherlands.
Johan Van SoestDepartment of Radiation Oncology (MAASTRO), Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands.
Inge Van OortDepartment of Urology, Radboud university Medical Center, Nijmegen, the Netherlands.
Laura HochstenbachDepartment of Urology, Maastricht University Medical Center, the Netherlands.
Esther J Bloemen-van GurpDepartment of Radiation Oncology (MAASTRO), Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands.
Andre DekkerDepartment of Radiation Oncology (MAASTRO), Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands.
Rianne R R FijtenDepartment of Radiation Oncology (MAASTRO), Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aims to develop and externally validate a clinically plausible Bayesian network structure to predict one-year erectile dysfunction in prostate cancer patients by combining expert knowledge with evidence from data using clinical and Patient-reported outcome measures (PROMs) data. In addition, compare and contrast structures that stem from PROM information and routine clinical data. Summary of background: For men with localized prostate cancer, choosing the optimal treatment can be challenging since each option comes with different side effects, such as erectile dysfunction, which negatively impacts their quality of life. Our previous findings demonstrate that logistic regression models are able to identify patients at high risk of erectile dysfunction. However, methods such as Bayesian networks may be more successful, as they intricately represent the causal relations between the variables. Patients and methods: 946 prostate cancer patients from 65 Dutch hospitals were considered to develop the Bayesian network structure. Continuous variables were discretized before analysis based on expert opinions and literature. Patients with missing information and variables with more than 25% of missing information were excluded. Prostate cancer treating physicians first determined the relationships (arcs) between the available variables. The structures were then modified based on algorithmically derived structures using the hill-climbing algorithm. Structural Performance was evaluated based on the area under the curve (AUC) values and calibration plots on the training and test data. Results: BMI and prostate volume via MRI were excluded from this analysis due to their high percentage of missingness ( Conclusion: Bayesian network structures derived from PROM information by complimenting expert knowledge with evidence from the data produce a clinically plausible structure that is more performant than structures from clinical data. Our study supports the growing global recognition of incorporating the patient's perspective in outcomes research for better decision-making and optimal outcomes. However, a structure that combines both sources of information gives a more holistic view of the patient with actionable insights and improved discriminative power.

Identifiers

PMID39188594
PMCPMC11345401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.